MorphoSys to Present at J.P. Morgan Healthcare Conference

2013-01-03 15:03:48 -
MorphoSys AG /
MorphoSys to Present at J.P. Morgan Healthcare Conference
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 



MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its
management will present at the upcoming J.P. Morgan Healthcare Conference in San
Francisco.


J.P. Morgan Healthcare Conference
Date:           January 10, 2013, 11:00 am PST (2:00 pm EST, 7:00 pm GMT, 8:00
pm CET)
Venue:        San Francisco, CA, USA
Presenter:   Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG


The  PDF version of the presentation  will be provided at www.morphosys.com. The
link to the webcast will be filed under www.morphosys.com/conference-calls.




About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, 
  
    
      
        

	    
  
  MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit  www.morphosys.com

HuCAL(®),  HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®)  and  100 billion  high  potentials(®)  are registered trademarks of
MorphoSys AG

Slonomics(®)  is  a  registered  trademark  of  Sloning  BioTechnology  GmbH,  a
subsidiary of MorphoSys AG.




This  communication contains  certain forward-looking  statements concerning the
MorphoSys  group of  companies. The  forward-looking statements contained herein
represent  the judgment of MorphoSys as of  the date of this release and involve
risks  and  uncertainties.  Should  actual  conditions differ from the Company's
assumptions,  actual  results  and  actions  may  differ from those anticipated.
MorphoSys  does not intend to update  any of these forward-looking statements as
far as the wording of the relevant press release is concerned.


For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com

Media Release (PDF): 
 hugin.info/130295/R/1668012/541551.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1668012]